A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. - Wikidata - awgldk - TriplyDB

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

http://www.wikidata.org/entity/Q33767209

about

Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.A novel quantitative kinase assay using bacterial surface display and flow cytometry Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance Emerging drugs for chronic myeloid leukemia.Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Controlling the Mdm2-Mdmx-p53 Circuit.A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.Oncogenes come of age.Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Philadelphia positive acute lymphoblastic leukaemia of childhood.Second-generation kinase inhibitors.Recent advances in targeted therapy of human myelogenous leukaemia.Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?Emerging drugs in chronic myelogenous leukaemia.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Stat5 as a diagnostic marker for leukemia.Current status of therapy for chronic myeloid leukemia: a review of drug development.Imatinib mesylate for the treatment of chronic myeloid leukemia.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors.Current status of agents active against the T315I chronic myeloid leukemia phenotype.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Development of an effective therapy for chronic myelogenous leukemia Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.High-throughput determination of mode of inhibition in lead identification and optimization.Allosteric lariat peptide inhibitors of Abl kinase.Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

P2860

Q24814879-0371F888-59C7-4AF9-B9F5-0D8A20F3F3C1 Q28535179-53E495D3-DDB5-45C0-8B0B-E2BB7C57C10E Q30666276-450AB0EE-4F33-42F6-B4CF-9F12F378948E Q33536762-63A02E2A-A53A-42A0-A466-6F0F377BE425 Q33847866-94E426C4-85FB-4841-B762-7CE40CCF35DD Q33869316-E7A83B3D-5A52-43CF-AA56-FB40436FC71B Q33906140-837EC9B6-E6A3-4030-ADDC-3B412F03AA02 Q34011009-1ECE66BF-F6D7-4857-B298-EB8444BDD9B1 Q34052015-F80E9333-4269-461F-AC62-56D50903EAC9 Q34625756-A143D908-C000-4C7C-9861-1BCD3A6482FC Q34983846-90CD7096-FC18-45FC-8E41-520B62362FEC Q34992505-672CD1C0-78DB-4BB6-82C1-8FCDF26BFCC1 Q35623817-110F76B4-8AB5-4235-B1A4-1B620426CBDC Q35751017-1020F756-E08C-41A7-A18E-40892E558C31 Q35849543-5BF36B5C-E521-4381-AE2E-F7BB5F0E7E96 Q36158713-9236A71C-E197-4F97-9065-A0BF62A0F3B7 Q36228062-DBA54F75-7ECF-43F8-BB79-BA76C960577D Q36268315-9B940F93-B8CB-45C2-97D8-2BB6D5978084 Q36318531-AF2B28C3-9448-49F0-8841-4D68708A2C40 Q36328410-44200C9C-C9E6-4390-810E-573B40A61799 Q36634266-46B37DA2-36CA-4010-9460-17FED4706D8F Q36822880-778C7425-6750-42DC-BE26-1EFB2EEC53EC Q37035281-C7ABDB30-FECD-4033-B238-1A45C4A725E9 Q37179388-AE27315E-256B-4312-9039-E938B23A84A8 Q37183434-F66107ED-646E-4F76-9AB5-1E7099100E42 Q37256808-CC56091A-F9C2-4828-B021-DC10883B9DFE Q37586848-B27DB287-EE03-478F-A5C6-8A6397A93948 Q37665845-C9B880CF-02FC-4DF6-9327-3711B1D86342 Q37847179-75400EC1-7A88-4338-B24A-4BCABF214905 Q37921836-DC2FD319-B0E3-43E0-AD4F-B035F35081DD Q37966917-1C70E3EE-6865-477D-9B4C-A5051EBE4CE0 Q38050752-15E78CF1-3AAE-4368-8281-D4AB12B4552C Q38090664-DFF0F56C-93B4-456A-A408-D65C07A94D86 Q38261599-8B4AF3A5-5304-441F-A0F2-32958DF07AE3 Q38449116-0D6939D3-FAB4-4013-A249-9F9DF2CD9A7C Q39096584-C3FD2D22-883D-404A-A31E-E78993346CEB Q39355501-DF368462-E13E-40AF-BE35-182EDC7060F3 Q41673629-6A5A6FD7-5FDC-43E3-A394-68F2A9A56C7C Q42195868-D8BFEADD-6610-48EA-AD98-66C3578CF072 Q43078241-9360569E-0A0D-459D-897D-020490443F3F

P2860

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

http://www.wikidata.org/entity/Q33767209

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@ast

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@en

type

label

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@ast

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@en

prefLabel

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@ast

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@en

P1433

Q33767209-CE29B6F0-1405-483F-A102-60BDDCEE7CDA

P1476

Q33767209-26E8329C-6AF5-4ABB-A512-D16D9E24A807

P2093

Q33767209-006F00C6-C372-45D0-B247-D2F2BBFB6B64

Q33767209-196711D9-9B0F-4BB2-8E5A-7A9998632337

Q33767209-19818F0D-711F-4864-A503-677D740700D4

Q33767209-33E4A7AC-49D6-4CD2-96A6-E6E9EEB5E1F5

Q33767209-4523CC18-A670-4A26-B42A-F292DF5CA2AE

Q33767209-AD03060F-03DE-45CF-825B-6024F0980D79

Q33767209-B6846D8F-6C3B-4880-9E8B-628CDC8126AF

Q33767209-E6C86D4F-DA13-42F5-BE8E-5D8F28372962

P2860

Q33767209-03AA4C97-667B-40B2-8779-20C606812D8F

Q33767209-04F67EC3-6415-470F-B6B2-109125F08006

Q33767209-0CB64D1B-6211-4FED-895E-05F43270A250

Q33767209-13E8A7D4-67EF-4BD6-88DD-29EA6C21E4EA

Q33767209-1E86877E-79AA-4196-BED5-CE3657635DE2

Q33767209-2651330B-E1D4-41DB-B20D-040474B858AB

Q33767209-2FB57847-CE72-49B3-87DB-47E0DB613B60

Q33767209-30DA921A-1F49-4C61-8629-A7B53B020915

Q33767209-4F3F0BCA-7F40-46CF-AF3A-D8728137EDA4

Q33767209-4F817258-3875-4DCC-805C-48BCB4F607D1

P304

Q33767209-E059EDAA-8167-4F76-A4E4-2475FE3D9185

P31

Q33767209-AD20C30B-FDEE-4C2D-99CD-CB275D62375B

P356

Q33767209-C1F3BBE9-9BC3-4843-8EE9-5F9F580E0D24

P407

Q33767209-22FFB76F-36F9-4505-8D5F-B517C2F562C4

P433

Q33767209-EDE6D886-A612-415F-BB21-2805A7F3A041

P478

Q33767209-A90AE21C-1AE5-485E-9716-6B0ABB7A4BDA

P50

Q33767209-8238704D-CD38-4458-8BA9-0FEB45CCFBDB

P577

Q33767209-2CE240C1-6FBD-40E5-B9BB-3F350100B7DC

P5875

Q33767209-91177B37-F0B3-484E-BFAB-DCC5FA968B8F

P698

Q33767209-6CA20BB9-6166-480E-AD16-70A5EEA3E220

P932

Q33767209-830A6B08-C496-4CD7-8EAA-361D33C3C659

P356

PNAS.0408283102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

@en

P2093

Anthony D Kang

http://www.w3.org/2001/XMLSchema#string

E Premkumar Reddy

http://www.w3.org/2001/XMLSchema#string

Kimberly A Robell

http://www.w3.org/2001/XMLSchema#string

Kiranmai Gumireddy

http://www.w3.org/2001/XMLSchema#string

M V Ramana Reddy

http://www.w3.org/2001/XMLSchema#string

Premila John

http://www.w3.org/2001/XMLSchema#string

Stacey J Baker

http://www.w3.org/2001/XMLSchema#string

Stephen C Cosenza

http://www.w3.org/2001/XMLSchema#string

P2860

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Structural organization of the bcr gene and its role in the Ph' translocation

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Overriding imatinib resistance with a novel ABL kinase inhibitor

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

Constitutive synthesis of interleukin-3 by leukaemia cell line WEHI-3B is due to retroviral insertion near the gene.

The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.

P304

1992-1997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0408283102

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Kiranmai Gumireddy

P577

2005-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8053827

http://www.w3.org/2001/XMLSchema#string

P698

15677719

http://www.w3.org/2001/XMLSchema#string

P932

546016

http://www.w3.org/2001/XMLSchema#string